Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations (Q44613047)

4 December 2017

title

Mechanistic basis for reduced viral and enzymatic fitness of HIV-1 reverse transcriptase containing both K65R and M184V mutations (English)

1 reference

4 December 2017

Bruno Canard

1 reference

4 December 2017

Jérôme Deval

1 reference

4 December 2017

Kirsten L White

1 reference

4 December 2017

Michael D Miller

1 reference

4 December 2017

Neil T Parkin

1 reference

4 December 2017

Jérôme Courcambeck

1 reference

4 December 2017

Philippe Halfon

1 reference

4 December 2017

Boulbaba Selmi

1 reference

4 December 2017

Joëlle Boretto

1 reference

4 December 2017

language of work or name

English

0 references

publication date

9 October 2003

1 reference

Journal of Biological Chemistry

4 December 2017

published in

1 reference

4 December 2017

volume

279

1 reference

4 December 2017

1 reference

4 December 2017

page(s)

509-516

1 reference

Antiviral drugs: current state of the art.

4 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Targeting HIV: antiretroviral therapy and development of drug resistance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus resistance to nucleoside inhibitors zidovudine and 3-TC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Phenotypic mechanism of HIV-1 resistance to 3'-azido-3'-deoxythymidine (AZT): increased polymerization processivity and enhanced sensitivity to pyrophosphate of the mutant viral reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Fitness of drug resistant HIV-1: methodology and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Prolonged CD4+ cell/virus load discordance during treatment with protease inhibitor-based highly active antiretroviral therapy: immune response and viral control

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

The M184V mutation in the reverse transcriptase of human immunodeficiency virus type 1 impairs rescue of chain-terminated DNA synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

The M184V mutation reduces the selective excision of zidovudine 5'-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Genotypic and phenotypic analyses of HIV-1 in antiretroviral-experienced patients treated with tenofovir DF.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Molecular mechanisms of resistance to human immunodeficiency virus type 1 with reverse transcriptase mutations K65R and K65R+M184V and their effects on enzyme function and viral replication capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

An integrated system to study multiply substituted human immunodeficiency virus type 1 reverse transcriptase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Hydration free energy a fragmental model and drug design

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Lamivudine (3TC) resistance in HIV-1 reverse transcriptase involves steric hindrance with beta-branched amino acids

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Increased polymerase fidelity of the 3TC-resistant variants of HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Evolution of lamivudine resistance in human immunodeficiency virus type 1-infected individuals: the relative roles of drift and selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Evidence of a role for the Q151L mutation and the viral background in development of multiple dideoxynucleoside-resistant human immunodeficiency virus type 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Altered drug sensitivity, fitness, and evolution of human immunodeficiency virus type 1 with pol gene mutations conferring multi-dideoxynucleoside resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Resistance to 2',3'-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Identification of a mutation at codon 65 in the IKKK motif of reverse transcriptase that encodes human immunodeficiency virus resistance to 2',3'-dideoxycytidine and 2',3'-dideoxy-3'-thiacytidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Effects of dipeptide insertions between codons 69 and 70 of human immunodeficiency virus type 1 reverse transcriptase on primer unblocking, deoxynucleoside triphosphate inhibition, and DNA chain elongation

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Pyrimidine nucleotide and nucleic acid synthesis in human monocytes and macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Simultaneous determination of pyrimidine or purine deoxyribonucleoside triphosphates using a polymerase assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Low levels of deoxynucleotides in peripheral blood lymphocytes: a strategy to inhibit human immunodeficiency virus type 1 replication

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Diminished RNA primer usage associated with the L74V and M184V mutations in the reverse transcriptase of human immunodeficiency virus type 1 provides a possible mechanism for diminished viral replication capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

The molecular mechanism of multidrug resistance by the Q151M human immunodeficiency virus type 1 reverse transcriptase and its suppression using alpha-boranophosphate nucleotide analogues

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

A mechanism of AZT resistance: an increase in nucleotide-dependent primer unblocking by mutant HIV-1 reverse transcriptase

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Mechanism-based suppression of dideoxynucleotide resistance by K65R human immunodeficiency virus reverse transcriptase using an alpha-boranophosphate nucleoside analogue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Proposed alternatives for the use of anti-HIV drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

Helicobacter pylori urease significantly reduces opsonization by human complement

21 January 2018

1 reference

https://api.crossref.org/works/10.1074%2FJBC.M308806200

21 January 2018

Identifiers

DOI

10.1074/JBC.M308806200

1 reference

4 December 2017

1 reference